Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | terminated | Early Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | terminated | Early Phase 1 | 5 | Samus Therapeutics, Inc.INDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03173430 | Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma | terminated | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Nov 12, 2024source: clinicaltrials